For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and Tafamidis meglumine represents a true breakthrough . These groundbreaking therapies preserve the transthyretin protein, halting its destructive build-up and lessening the burden of the illness. Patients are now seeing posit